Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Director | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenetic Biosciences, Inc.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2035-12-31 | Direct | 2,500 |
Reported balance
After 2025-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-31 · Grant · Acquired 2,500 · Balance 2,500 F1: The Options vest 100% on the twelve-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest 100% on the twelve-month anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Jan 5, 2026 17:00 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001683168-26-000103 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2035-12-31 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 17:00 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001683168-24-008718 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2034-12-11 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 17:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001683168-23-008737 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-12-06 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 17:02 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001683168-22-008322 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 17:40 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001683168-21-006229 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 17:01 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001683168-20-004204 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-04 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 18:28 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001683168-19-003913 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The Options vest 100% on the twelve month anniversary of the grant date. Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 17:24 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001662252-18-000106 · ownership.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-11-28 F1 · derivative.exercise_date: The Options vest in equal quarterly installments over the twelve-month period commencing on the grant date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 17:39 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001662252-17-000232 · form4.xml · derivative · entry 1 Dastoor Firdaus J. · CIK 0001690576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-15 F1 · derivative.exercise_date: On November 15, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on November 15, 2017 of $2.18. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.